Zyversa Therapeutics Stock Probability of Future Stock Price Finishing Over 1.02
| ZVSA Stock | 1.17 0.03 2.63% |
ZyVersa |
ZyVersa Therapeutics Target Price Odds to finish over 1.02
The tendency of ZyVersa Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above 1.02 in 90 days |
| 1.17 | 90 days | 1.02 | about 88.07 |
Based on a normal probability distribution, the odds of ZyVersa Therapeutics to stay above 1.02 in 90 days from now is about 88.07 (This ZyVersa Therapeutics probability density function shows the probability of ZyVersa Stock to fall within a particular range of prices over 90 days) . Probability of ZyVersa Therapeutics price to stay between 1.02 and its current price of 1.17 at the end of the 90-day period is about 6.19 .
Given the investment horizon of 90 days ZyVersa Therapeutics has a beta of -3.31. This usually means as returns on its benchmark rise, returns on holding ZyVersa Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, ZyVersa Therapeutics is expected to outperform its benchmark. Additionally ZyVersa Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. ZyVersa Therapeutics Price Density |
| Price |
Predictive Modules for ZyVersa Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ZyVersa Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ZyVersa Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ZyVersa Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ZyVersa Therapeutics is not an exception. The market had few large corrections towards the ZyVersa Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ZyVersa Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ZyVersa Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.55 | |
β | Beta against Dow Jones | -3.31 | |
σ | Overall volatility | 0.56 | |
Ir | Information ratio | -0.08 |
ZyVersa Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ZyVersa Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ZyVersa Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ZyVersa Therapeutics generated a negative expected return over the last 90 days | |
| ZyVersa Therapeutics has high historical volatility and very poor performance | |
| ZyVersa Therapeutics may become a speculative penny stock | |
| ZyVersa Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (98.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ZyVersa Therapeutics generates negative cash flow from operations | |
| ZyVersa Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: ZyVersa Therapeutics CEO, Stephen C. Glover, to Attend JPMs Healthcare Conference 2025 in San Francisco |
ZyVersa Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ZyVersa Stock often depends not only on the future outlook of the current and potential ZyVersa Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ZyVersa Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 97.5 K | |
| Cash And Short Term Investments | 3.1 M |
ZyVersa Therapeutics Technical Analysis
ZyVersa Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. ZyVersa Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of ZyVersa Therapeutics. In general, you should focus on analyzing ZyVersa Stock price patterns and their correlations with different microeconomic environments and drivers.
ZyVersa Therapeutics Predictive Forecast Models
ZyVersa Therapeutics' time-series forecasting models is one of many ZyVersa Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary ZyVersa Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about ZyVersa Therapeutics
Checking the ongoing alerts about ZyVersa Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for ZyVersa Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| ZyVersa Therapeutics generated a negative expected return over the last 90 days | |
| ZyVersa Therapeutics has high historical volatility and very poor performance | |
| ZyVersa Therapeutics may become a speculative penny stock | |
| ZyVersa Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (98.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ZyVersa Therapeutics generates negative cash flow from operations | |
| ZyVersa Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: ZyVersa Therapeutics CEO, Stephen C. Glover, to Attend JPMs Healthcare Conference 2025 in San Francisco |
Check out ZyVersa Therapeutics Backtesting, ZyVersa Therapeutics Valuation, ZyVersa Therapeutics Correlation, ZyVersa Therapeutics Hype Analysis, ZyVersa Therapeutics Volatility, ZyVersa Therapeutics History as well as ZyVersa Therapeutics Performance. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 491.97 | Return On Assets (0.25) | Return On Equity (1.52) |
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.